Designs for phase I cancer clinical trials with differentiation of graded toxicity

Communications in Statistics - Theory and Methods

Volumn 29, Issue 5-6, 2000, Pages 975-987

  Wang, Chinying ^a   Chen, T Timothy ^b   Tyan, Irvin ^c  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Continual reassessment method; Dose ranging study; Maximum tolerated dose

Indexed keywords

EID: 26844536305     PISSN: 03610926     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Baker, S. A. (1990). "Examination of designs for phase I clinical trials. Eleventh Annual Meeting of the Society for Clinical Trials", Controlled Clinical Trials, 11, 253-308.
2. Chevret, S. (1991). "The continual reassessment method in cancer phase I clinical trials: a simulation study", Statistics in Medicine, 12, 1093-1108.
3. Korn, E. L., Midthune, D., Chen, T. T., Christian, M. C., and Simon, R. (1994). "A Comparison of Two Phase I Trial Designs", Statistics in Medicine, 13, 1799-1806.
4. National Cancer Institute. (1993). Investigator's Handbook, A Manual for Participants in Clinical Trials of Investigational Agents Sponsored by the Division of Cancer Treatment, National Cancer Institute.
5. O'Quigley, J., Pepe, M. and Fisher, L. (1990). "Continual reassessment method: a practical design for phase I clinical trials in cancer", Biometrics, 46 33-48.
6. O'Quigley, J. and Chevret, S. (1991). "Methods for dose finding studies in cancer clinical trials. A review and results of a Monte Carlo study", Statistics in Medicine, 10, 1647-1664.
7. Storer, B. E. (1989). "Design and analysis of Phase I Clinical Trials" Biometrics, 45, 925-937.
8. WHO (1979). WHO Handbook for Reporting Results of Cancer Treatment., WHO Offset Publication 48, WHO, Geneva.